We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
Read MoreHide Full Article
Dr. Reddy’s Laboratories Ltd (RDY - Free Report) announced that it has received approval from the Drugs Control General of India (DCGI) to conduct a phase III studyon Russia's Sputnik V vaccine for the treatment of COVID-19 in India. The company expects to begin the study this month. The placebo-controlled study will be conducted in1500 patients in India.
In September 2020, Dr. Reddy’s partnered with the Russian Direct Investment Fund (RDIF), the company which is marketing the Sputnik V vaccine, to conduct clinical studies on the vaccineand for its distribution rights in India.
Sputnik V was developed by Moscow’s Gamaleya National Research Institute of Epidemiology and Microbiology and registered as the world’s first vaccine against COVID-19.
Shares of the company have surged 67.4% in the past year compared with the industry’s growth of 15.7%.
The phase III study was recommended after the Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase II study of the vaccine. No safety concerns were identified and the phase II study met the primary endpoints of safety.
In January 2021, Moderna, Inc.’s (MRNA - Free Report) mRNA-based coronavirus vaccine candidate, mRNA-1273, was granted a conditional marketing authorization (CMA) by the European Commission. The vaccine can be administered for active immunization to prevent COVID-19 in individuals 18 years of age and older. It also received authorization in the United States and a few other countries.
AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, received authorization for emergency use in the United Kingdom. This was the first approval or authorization for the candidate anywhere in the world and the second authorization for any coronavirus vaccine in the U.K.
Pfizer (PFE - Free Report) and its partner BioNTech’s mRNA-based COVID-19 vaccine, BNT162b2, is approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
Dr. Reddy’s Laboratories Ltd (RDY - Free Report) announced that it has received approval from the Drugs Control General of India (DCGI) to conduct a phase III studyon Russia's Sputnik V vaccine for the treatment of COVID-19 in India. The company expects to begin the study this month. The placebo-controlled study will be conducted in1500 patients in India.
In September 2020, Dr. Reddy’s partnered with the Russian Direct Investment Fund (RDIF), the company which is marketing the Sputnik V vaccine, to conduct clinical studies on the vaccineand for its distribution rights in India.
Sputnik V was developed by Moscow’s Gamaleya National Research Institute of Epidemiology and Microbiology and registered as the world’s first vaccine against COVID-19.
Shares of the company have surged 67.4% in the past year compared with the industry’s growth of 15.7%.
The phase III study was recommended after the Data and Safety Monitoring Board (DSMB) reviewed the safety data from the phase II study of the vaccine. No safety concerns were identified and the phase II study met the primary endpoints of safety.
In January 2021, Moderna, Inc.’s (MRNA - Free Report) mRNA-based coronavirus vaccine candidate, mRNA-1273, was granted a conditional marketing authorization (CMA) by the European Commission. The vaccine can be administered for active immunization to prevent COVID-19 in individuals 18 years of age and older. It also received authorization in the United States and a few other countries.
AstraZeneca’s (AZN - Free Report) adenovirus-based coronavirus vaccine candidate, AZD1222, received authorization for emergency use in the United Kingdom. This was the first approval or authorization for the candidate anywhere in the world and the second authorization for any coronavirus vaccine in the U.K.
Pfizer (PFE - Free Report) and its partner BioNTech’s mRNA-based COVID-19 vaccine, BNT162b2, is approved for emergency/temporary/conditional use in more than 40 countries, including the United States and 27 EU member countries.
Zacks Rank
Dr. Reddy’scurrently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dr. Reddys Laboratories Ltd Price
Dr. Reddys Laboratories Ltd price | Dr. Reddys Laboratories Ltd Quote
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>